Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2014

View Archived Issues

Phase I results presented for the new PET tracer [18F]-FSPG

Foamix begins phase II trial of FDX-104 to prevent EGFR inhibitor-induced rash

Merck Serono, the ICR and the Wellcome Trust collaborate to discover tankyrase inhibitors

NanoString Technologies and Brigham and Women's Hospital collaborate to develop cancer diagnostics

MicroRNA identified as a biomarker target for MS

Interim phase II results for squalamine lactate plus ranibizumab in neovascular AMD

SNP signature linked to response to glatiramer in patients with MS

AbbVie discloses novel CDK9/cyclin-T1 inhibitors for cancer

BNN-93, a novel neuroprotective ocular solution

Researchers at Oncodesign patent novel RIP-2 inhibitors

Sanofi divulges new SGK1 inhibitors

Researchers in London prepare novel SSAO inhibitors for COPD and other disorders

A team of scientists at Novartis synthesize new complement C5 convertase inhibitors

FDA grants orphan drug status to DNX-2401 for glioma

MacroGenics begins phase I study of MGD-007

FDA grants fast track designation to NurOwn for ALS

DiscoveryBioMed receives grant for ADPKD drug development

StemCells begins phase II trial of HuCNS-SC in cervical SCI

NIAID awards grant to Hampton University for work in infectious disease

Bristol-Myers Squibb withdraws NDA for asunaprevir

Generex Biotechnology explores opportunities for Antigen Express technology against Ebola

Orphazyme prepares phase II/III trial of arimoclomol in Niemann-Pick disease type C

Lead Discovery Center and UiT The Arctic University of Norway seek drugs in arctic sea organisms

Second Genome partners with Mayo Clinic to develop microbiome therapeutics

Cardio3 BioSciences gains preferred access to Mayo Clinic technologies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...